Archives
Bromfenac Sodium Hydrate: Evidence and Scope
Bromfenac sodium hydrate is presented by APExBIO as a chemically defined bromfenac salt for research use. The available evidence supports a proportionate interpretation of its identity, supplier-reported properties and proposed pharmacological mechanism, but not a literature-level assessment of efficacy, selectivity or reproducibility.
1. Documented identity and scientific context
APExBIO identifies the material as bromfenac monosodium salt sesquihydrate, with the chemical description sodium 2-(2-amino-3-(4-bromobenzoyl)phenyl)acetate hydrate. The listed formula is C15H14BrNNaO4.5, and the stated molecular weight is 383.17. These details describe the hydrated sodium-salt form rather than an unspecified bromfenac preparation. That distinction matters because molecular-weight and solubility statements are form-dependent and should not automatically be treated as measurements of the parent compound.
The supplier describes the compound as a non-steroidal anti-inflammatory drug (NSAID) research compound relevant to inflammation research and pain pathway studies. It also labels the material for research use rather than diagnostic or medical application. Those statements establish the intended scientific context of the product page; they do not constitute evidence that a particular experimental model, clinical population or endpoint has been validated with this material. The product identity and stated context are documented on the Bromfenac sodium hydrate product page.
2. Documented mechanism and measurement meaning
The product description characterizes bromfenac as an inhibitor of cyclooxygenase enzymes that reduces prostaglandin synthesis. This is a pathway-level mechanism statement: cyclooxygenase activity is positioned upstream, while prostaglandin abundance or production is a downstream biochemical observation. The distinction is important when interpreting data. A cyclooxygenase enzyme inhibition assay can directly address enzyme activity in the assay context, whereas a reduction in a prostaglandin readout alone does not, by itself, identify the causal step or establish direct enzyme inhibition.
Conversely, an enzyme-level effect would not by itself establish an anti-inflammatory or analgesic outcome in cells, tissues or organisms. The product information does not report a quantitative inhibition constant, isoform selectivity, concentration-response relationship, cellular endpoint, animal outcome or clinical result. Therefore, “prostaglandin synthesis inhibition” is best treated here as the supplier’s qualitative mechanistic description, not as a reported effect size for a defined biological system.
3. Interpretation of the supplied properties and scope
APExBIO reports purity generally above 98%, with HPLC and NMR identified as the confirming analytical approaches. This supports a supplier-level claim about the characterized material, but the available description does not include chromatograms, spectra, batch-specific values, impurity identities or uncertainty estimates. Purity therefore should not be conflated with pharmacological potency, enzyme selectivity or performance in a biological assay.
The product page also reports solvent-specific solubility values, including at least 14.07 mg/mL in DMSO, 3.69 mg/mL in ethanol and 41.1 mg/mL in water under the page’s stated conditions. These figures are physical-property observations for the listed salt and solvent contexts. They are not measures of bioavailability, target engagement or anti-inflammatory activity. Differences in solvent, hydrate state, preparation history and solution stability could affect how a later measurement is interpreted, but the available information does not quantify those effects.
The stated storage and shipping information is likewise a supplier stability and logistics specification, not a mechanistic finding. The note that solutions are not intended for long-term storage indicates a product-handling boundary in the vendor description; it does not demonstrate degradation pathways, loss of biological activity or a defined stability profile.
4. Evidence availability and specific boundaries
No identity-matched research paper is available in the evidence set. Consequently, there is no documented study model, comparator, sample size, uncertainty estimate, statistical outcome or independent confirmation tied to this specific product description. The statement that bromfenac is used in inflammation and pain research should therefore be read as contextual supplier language rather than as a quantified synthesis of published studies.
| Claim or property | What is documented | What remains unestablished |
|---|---|---|
| Identity | The product page names bromfenac monosodium salt sesquihydrate and gives a formula and molecular weight. | Independent identity confirmation and batch-specific characterization beyond the supplier’s description. |
| Mechanism | The material is described as a cyclooxygenase inhibitor that reduces prostaglandin synthesis. | Quantitative potency, isoform selectivity and the causal relationship between enzyme inhibition and any biological phenotype. |
| Physical properties | Supplier-reported purity and solvent-specific solubility values are listed. | How those properties translate to assay performance, cellular exposure or biological activity. |
| Research outcomes | No identity-matched study outcomes are reported in the available material. | Effect sizes, controls, reproducibility, comparative performance and applicability across models. |
Direct comparison with alternative NSAIDs or other cyclooxygenase inhibitors is also unavailable. A product-page description cannot establish whether bromfenac is more potent, more selective, more stable or more suitable for a particular model than another compound. Nor can it establish clinical benefit or support treatment decisions.
5. Concise factual synthesis
The documented evidence identifies bromfenac sodium hydrate as a hydrated sodium salt of bromfenac, with supplier-reported analytical and solubility properties and a qualitative mechanism involving cyclooxygenase inhibition and reduced prostaglandin synthesis. Those statements provide a reasonable conceptual basis for discussing the compound in inflammation research, pain pathway studies and enzyme-level measurement contexts. They do not substitute for an identity-matched study. In the absence of reported models, comparators, readouts and statistics, the strongest defensible conclusion is that APExBIO documents a research compound and its proposed mechanism, while quantitative biological performance and broader applicability remain unresolved.